IL13RA2 and central nervous system cancer: However, a higher level of IL13Ra2 expression was observed in pontine gliomas (vs. midbrain gliomas, p = 0.0099, Figure 2C), DIPGs (vs. non-DIPG, p = 0.0013, Figure 2D), H3F3A-mutant gliomas (vs. the H3F3A wild-type, p < 0.0001, Figure 2E), as well as WHO grade IV gliomas (vs. grade I or II gliomas, p < 0.0001, Figure 2F), indicating distinct IL13Ra2 expression patterns among different BSGs.